<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34681616</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>20</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>RNA Editing: A New Therapeutic Target in Amyotrophic Lateral Sclerosis and Other Neurological Diseases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10958</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222010958</ELocationID><Abstract><AbstractText>The conversion of adenosine to inosine in RNA editing (A-to-I RNA editing) is recognized as a critical post-transcriptional modification of RNA by adenosine deaminases acting on RNAs (ADARs). A-to-I RNA editing occurs predominantly in mammalian and human central nervous systems and can alter the function of translated proteins, including neurotransmitter receptors and ion channels; therefore, the role of dysregulated RNA editing in the pathogenesis of neurological diseases has been speculated. Specifically, the failure of A-to-I RNA editing at the glutamine/arginine (Q/R) site of the GluA2 subunit causes excessive permeability of &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors to Ca<sup>2+</sup>, inducing fatal status epilepticus and the neurodegeneration of motor neurons in mice. Therefore, an RNA editing deficiency at the Q/R site in GluA2 due to the downregulation of ADAR2 in the motor neurons of sporadic amyotrophic lateral sclerosis (ALS) patients suggests that Ca<sup>2+</sup>-permeable AMPA receptors and the dysregulation of RNA editing are suitable therapeutic targets for ALS. Gene therapy has recently emerged as a new therapeutic opportunity for many heretofore incurable diseases, and RNA editing dysregulation can be a target for gene therapy; therefore, we reviewed neurological diseases associated with dysregulated RNA editing and a new therapeutic approach targeting dysregulated RNA editing, especially one that is effective in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hosaka</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Tsukuba University Hospital Kensei Area Medical Education Center, Chikusei 308-0813, Ibaraki, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Ibaraki Western Medical Center, Chikusei 308-0813, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Shinjuku-ku, Tokyo 160-0023, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>19K23957</GrantID><Agency>Japan Society for the Promotion of Science</Agency><Country/></Grant><Grant><GrantID>202010135</GrantID><Agency>Uehara Memorial Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.5.4.4</RegistryNumber><NameOfSubstance UI="D000243">Adenosine Deaminase</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6W5IXV8V9</RegistryNumber><NameOfSubstance UI="C104722">glutamate receptor ionotropic, AMPA 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000243" MajorTopicYN="N">Adenosine Deaminase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="N">Nervous System Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017393" MajorTopicYN="N">RNA Editing</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RNA editing</Keyword><Keyword MajorTopicYN="N">adenosine deaminase acting on RNA 2 (ADAR2)</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">excitotoxicity</Keyword><Keyword MajorTopicYN="N">&#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors</Keyword></KeywordList><CoiStatement>The authors declare no competing financial interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34681616</ArticleId><ArticleId IdType="pmc">PMC8536083</ArticleId><ArticleId IdType="doi">10.3390/ijms222010958</ArticleId><ArticleId IdType="pii">ijms222010958</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001;344:1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R., Chi&#xf2; A., Traynor B.J. Novel genes associated with amyotrophic lateral sclerosis: Diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Dewil M., Robberecht W., Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener. Dis. 2005;2:147&#x2013;159. doi: 10.1159/000089620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089620</ArticleId><ArticleId IdType="pubmed">16909020</ArticleId></ArticleIdList></Reference><Reference><Citation>King A.E., Woodhouse A., Kirkcaldie M.T., Vickers J.C. Excitotoxicity in ALS: Overstimulation, or overreaction? Exp. Neurol. 2016;275:162&#x2013;171. doi: 10.1016/j.expneurol.2015.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.09.019</ArticleId><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown R.H., Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Campuzano A.G., Ortega A. Glutamate transporters: Critical components of glutamatergic transmission. Neuropharmacology. 2021;192:108602. doi: 10.1016/j.neuropharm.2021.108602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2021.108602</ArticleId><ArticleId IdType="pubmed">33991564</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner A., Levitz J. Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron. 2018;98:1080&#x2013;1098. doi: 10.1016/j.neuron.2018.05.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.05.018</ArticleId><ArticleId IdType="pmc">PMC6484838</ArticleId><ArticleId IdType="pubmed">29953871</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynelis S.F., Wollmuth L.P., McBain C.J., Menniti F.S., Vance K.M., Ogden K.K., Hansen K.B., Yuan H., Myers S.J., Dingledine R. Glutamate receptor ion channels: Structure, regulation, and function. Pharmacol. Rev. 2010;62:405&#x2013;496. doi: 10.1124/pr.109.002451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.109.002451</ArticleId><ArticleId IdType="pmc">PMC2964903</ArticleId><ArticleId IdType="pubmed">20716669</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerchner G.A., Nicoll R.A. Silent synapses and the emergence of a postsynaptic mechanism for LTP. Nat. Rev. Neurosci. 2008;9:813&#x2013;825. doi: 10.1038/nrn2501.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn2501</ArticleId><ArticleId IdType="pmc">PMC2819160</ArticleId><ArticleId IdType="pubmed">18854855</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer M.L., Westbrook G.L., Guthrie P.B. Voltage-dependent block by Mg2+ of NMDA responses in spinal cord neurones. Nature. 1984;309:261&#x2013;263. doi: 10.1038/309261a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/309261a0</ArticleId><ArticleId IdType="pubmed">6325946</ArticleId></ArticleIdList></Reference><Reference><Citation>Niswender C.M., Conn P.J. Metabotropic glutamate receptors: Physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010;50:295&#x2013;322. doi: 10.1146/annurev.pharmtox.011008.145533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.011008.145533</ArticleId><ArticleId IdType="pmc">PMC2904507</ArticleId><ArticleId IdType="pubmed">20055706</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaitakis A., Constantakakis E., Smith J. The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in amyotrophic lateral sclerosis. Ann. Neurol. 1988;24:446&#x2013;449. doi: 10.1002/ana.410240314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410240314</ArticleId><ArticleId IdType="pubmed">2906529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Tsai G., Kuncl R.W., Clawson L., Cornblath D.R., Drachman D.B., Pestronk A., Stauch B.L., Coyle J.T. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 1990;28:18&#x2013;25. doi: 10.1002/ana.410280106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410280106</ArticleId><ArticleId IdType="pubmed">2375630</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw P.J., Forrest V., Ince P.G., Richardson J.P., Wastell H.J. CSF and plasma amino acid levels in motor neuron disease: Elevation of CSF glutamate in a subset of patients. Neurodegeneration. 1995;4:209&#x2013;216. doi: 10.1006/neur.1995.0026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/neur.1995.0026</ArticleId><ArticleId IdType="pubmed">7583686</ArticleId></ArticleIdList></Reference><Reference><Citation>Spreux-Varoquaux O., Bensimon G., Lacomblez L., Salachas F., Pradat P.F., Le Forestier N., Marouan A., Dib M., Meininger V. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: A reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J. Neurol. Sci. 2002;193:73&#x2013;78. doi: 10.1016/S0022-510X(01)00661-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(01)00661-X</ArticleId><ArticleId IdType="pubmed">11790386</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Martin L.J., Kuncl R.W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 1992;326:1464&#x2013;1468. doi: 10.1056/NEJM199205283262204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId><ArticleId IdType="pubmed">1349424</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaitakis A., Smith J., Mandeli J., Yahr M.D. Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis. Lancet. 1988;1:1015&#x2013;1018. doi: 10.1016/S0140-6736(88)91841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(88)91841-7</ArticleId><ArticleId IdType="pubmed">2896868</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin D., Thompson M.A., Nadler J.V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 1993;250:473&#x2013;476. doi: 10.1016/0014-2999(93)90037-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-2999(93)90037-I</ArticleId><ArticleId IdType="pubmed">8112408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G., Lacomblez L., Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L., Bensimon G., Leigh P.N., Guillet P., Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Al Khleifat A., Meurgey J.-H., Jones A., Leigh P.N., Bensimon G., Al-Chalabi A. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2012;65:CD001447. doi: 10.1002/14651858.CD001447.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub3</ArticleId><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>van Zundert B., Izaurieta P., Fritz E., Alvarez F.J. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. J. Cell. Biochem. 2012;113:3301&#x2013;3312. doi: 10.1002/jcb.24234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.24234</ArticleId><ArticleId IdType="pmc">PMC3886915</ArticleId><ArticleId IdType="pubmed">22740507</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S., Nicholson G.A., Kiernan M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131:1540&#x2013;1550. doi: 10.1093/brain/awn071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awn071</ArticleId><ArticleId IdType="pubmed">18469020</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P., Geevasinga N., Yiannikas C., Howells J., Kiernan M.C., Vucic S. Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: A prospective study. Lancet Neurol. 2015;14:478&#x2013;484. doi: 10.1016/S1474-4422(15)00014-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(15)00014-9</ArticleId><ArticleId IdType="pubmed">25843898</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanz O., Bageac D., Braun L., Traynor B.J., Lehky T.J., Floeter M.K. Cortical hyperexcitability in patients with C9ORF72 mutations: Relationship to phenotype. Muscle Nerve. 2016;54:264&#x2013;269. doi: 10.1002/mus.25047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25047</ArticleId><ArticleId IdType="pmc">PMC4940214</ArticleId><ArticleId IdType="pubmed">26799151</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Kiskinis E., Mellin C., Wiskow O., Han S.S., Sandoe J., Perez N.P., Williams L.A., Lee S., Boulting G., et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell. Rep. 2014;7:1&#x2013;11. doi: 10.1016/j.celrep.2014.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger B.J., Macklin E.A., Vucic S., McIlduff C.E., Paganoni S., Maragakis N.J., Bedlack R., Goyal N.A., Rutkove S.B., Lange D.J., et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021;78:186&#x2013;196. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M., Pinto S., Costa J., Evangelista T., Ohana B., Pinto A. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. 2010;11:456&#x2013;460. doi: 10.3109/17482968.2010.498521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.498521</ArticleId><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryberg H., Askmark H., Persson L.I. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol. Scand. 2003;108:1&#x2013;8. doi: 10.1034/j.1600-0404.2003.00111.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0404.2003.00111.x</ArticleId><ArticleId IdType="pubmed">12807386</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA. 1993;90:6591&#x2013;6595. doi: 10.1073/pnas.90.14.6591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.14.6591</ArticleId><ArticleId IdType="pmc">PMC46978</ArticleId><ArticleId IdType="pubmed">8393571</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L., Van Damme P., Bogaert E., Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim. Biophys. Acta. 2006;1762:1068&#x2013;1082. doi: 10.1016/j.bbadis.2006.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.002</ArticleId><ArticleId IdType="pubmed">16806844</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak S., Weiss J.H. Calcium-permeable AMPA channels in neurodegenerative disease and ischemia. Curr. Opin. Neurobiol. 2006;16:281&#x2013;287. doi: 10.1016/j.conb.2006.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2006.05.004</ArticleId><ArticleId IdType="pubmed">16698262</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal J.J., Seeburg P.H. A-to-I RNA editing: Effects on proteins key to neural excitability. Neuron. 2012;74:432&#x2013;439. doi: 10.1016/j.neuron.2012.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.04.010</ArticleId><ArticleId IdType="pmc">PMC3724421</ArticleId><ArticleId IdType="pubmed">22578495</ArticleId></ArticleIdList></Reference><Reference><Citation>Sommer B., K&#xf6;hler M., Sprengel R., Seeburg P.H. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell. 1991;67:11&#x2013;19. doi: 10.1016/0092-8674(91)90568-J.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(91)90568-J</ArticleId><ArticleId IdType="pubmed">1717158</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T., Yamashita T., Aizawa H., Tsuji S., Kakita A., Takahashi H., Kwak S. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol. Dis. 2012;45:1121&#x2013;1128. doi: 10.1016/j.nbd.2011.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.033</ArticleId><ArticleId IdType="pubmed">22226999</ArticleId></ArticleIdList></Reference><Reference><Citation>Henley J.M., Wilkinson K.A. Synaptic AMPA receptor composition in development, plasticity and disease. Nat. Rev. Neurosci. 2016;17:337&#x2013;350. doi: 10.1038/nrn.2016.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn.2016.37</ArticleId><ArticleId IdType="pubmed">27080385</ArticleId></ArticleIdList></Reference><Reference><Citation>Greger I.H., Khatri L., Ziff E.B. RNA editing at arg607 controls AMPA receptor exit from the endoplasmic reticulum. Neuron. 2002;34:759&#x2013;772. doi: 10.1016/S0896-6273(02)00693-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00693-1</ArticleId><ArticleId IdType="pubmed">12062022</ArticleId></ArticleIdList></Reference><Reference><Citation>Herguedas B., Watson J.F., Ho H., Cais O., Garcia-Nafria J., Greger I.H. Architecture of the heteromeric GluA1/2 AMPA receptor in complex with the auxiliary subunit TARP gamma8. Science. 2019;364:9011. doi: 10.1126/science.aav9011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aav9011</ArticleId><ArticleId IdType="pmc">PMC6513756</ArticleId><ArticleId IdType="pubmed">30872532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D., Watson J.F., Matthews P.M., Cais O., Greger I.H. Gating and modulation of a hetero-octameric AMPA glutamate receptor. Nature. 2021;594:454&#x2013;458. doi: 10.1038/s41586-021-03613-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03613-0</ArticleId><ArticleId IdType="pmc">PMC7611729</ArticleId><ArticleId IdType="pubmed">34079129</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M. Dysregulated A to I RNA editing and non-coding RNAs in neurodegeneration. Front. Genet. 2012;3:326. doi: 10.3389/fgene.2012.00326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2012.00326</ArticleId><ArticleId IdType="pmc">PMC3551214</ArticleId><ArticleId IdType="pubmed">23346095</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa Cruz P.H., Kawahara Y. RNA Editing in Neurological and Neurodegenerative Disorders. Methods Mol. Biol. 2021;2181:309&#x2013;330. doi: 10.1007/978-1-0716-0787-9_18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-0787-9_18</ArticleId><ArticleId IdType="pubmed">32729088</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Zhang Y., Yang X., Hao C., Duan H. Gene Therapy for Neurodegenerative Disease: Clinical Potential and Directions. Front. Mol. Neurosci. 2021;14:618171. doi: 10.3389/fnmol.2021.618171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2021.618171</ArticleId><ArticleId IdType="pmc">PMC8236824</ArticleId><ArticleId IdType="pubmed">34194298</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Roy S. Gene-based therapies for neurodegenerative diseases. Nat. Neurosci. 2021;24:297&#x2013;311. doi: 10.1038/s41593-020-00778-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00778-1</ArticleId><ArticleId IdType="pmc">PMC8394447</ArticleId><ArticleId IdType="pubmed">33526943</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell. Biol. 2016;17:83&#x2013;96. doi: 10.1038/nrm.2015.4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2015.4</ArticleId><ArticleId IdType="pmc">PMC4824625</ArticleId><ArticleId IdType="pubmed">26648264</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbarbary R.A., Lucas B.A., Maquat L.E. Retrotransposons as regulators of gene expression. Science. 2016;351:aac7247. doi: 10.1126/science.aac7247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac7247</ArticleId><ArticleId IdType="pmc">PMC4788378</ArticleId><ArticleId IdType="pubmed">26912865</ArticleId></ArticleIdList></Reference><Reference><Citation>Picardi E., Manzari C., Mastropasqua F., Aiello I., D&#x2019;Erchia A.M., Pesole G. Profiling RNA editing in human tissues: Towards the inosinome Atlas. Sci. Rep. 2015;5:14941. doi: 10.1038/srep14941.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep14941</ArticleId><ArticleId IdType="pmc">PMC4598827</ArticleId><ArticleId IdType="pubmed">26449202</ArticleId></ArticleIdList></Reference><Reference><Citation>Picardi E., Horner D.S., Pesole G. Single-cell transcriptomics reveals specific RNA editing signatures in the human brain. RNA. 2017;23:860&#x2013;865. doi: 10.1261/rna.058271.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.058271.116</ArticleId><ArticleId IdType="pmc">PMC5435858</ArticleId><ArticleId IdType="pubmed">28258159</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M.H., Li Q., Shanmugam R., Piskol R., Kohler J., Young A.N., Liu K.I., Zhang R., Ramaswami G., Ariyoshi K., et al. Dynamic landscape and regulation of RNA editing in mammals. Nature. 2017;550:249&#x2013;254. doi: 10.1038/nature24041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature24041</ArticleId><ArticleId IdType="pmc">PMC5723435</ArticleId><ArticleId IdType="pubmed">29022589</ArticleId></ArticleIdList></Reference><Reference><Citation>Heraud-Farlow J.E., Walkley C.R. What do editors do? Understanding the physiological functions of A-to-I RNA editing by adenosine deaminase acting on RNAs. Open Biol. 2020;10:200085. doi: 10.1098/rsob.200085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.200085</ArticleId><ArticleId IdType="pmc">PMC7574547</ArticleId><ArticleId IdType="pubmed">32603639</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W., Chendrimada T.P., Wang Q., Higuchi M., Seeburg P.H., Shiekhattar R., Nishikura K. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat. Struct. Mol. Biol. 2006;13:13&#x2013;21. doi: 10.1038/nsmb1041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1041</ArticleId><ArticleId IdType="pmc">PMC2950615</ArticleId><ArticleId IdType="pubmed">16369484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov A., Memczak S., Wyler E., Torti F., Porath H.T., Orejuela M.R., Piechotta M., Levanon E.Y., Landthaler M., Dieterich C., et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell. Rep. 2015;10:170&#x2013;177. doi: 10.1016/j.celrep.2014.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.019</ArticleId><ArticleId IdType="pubmed">25558066</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueter S.M., Dawson T.R., Emeson R.B. Regulation of alternative splicing by RNA editing. Nature. 1999;399:75&#x2013;80. doi: 10.1038/19992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19992</ArticleId><ArticleId IdType="pubmed">10331393</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon O., Di Segni A., Cesarkas K., Porath H.T., Marcu-Malina V., Mizrahi O., Stern-Ginossar N., Kol N., Farage-Barhom S., Glick-Saar E., et al. RNA editing by ADAR1 leads to context-dependent transcriptome-wide changes in RNA secondary structure. Nat. Commun. 2017;8:1440. doi: 10.1038/s41467-017-01458-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01458-8</ArticleId><ArticleId IdType="pmc">PMC5682290</ArticleId><ArticleId IdType="pubmed">29129909</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg E., Levanon E.Y. A-to-I RNA editing-immune protector and transcriptome diversifier. Nat. Rev. Genet. 2018;19:473&#x2013;490. doi: 10.1038/s41576-018-0006-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41576-018-0006-1</ArticleId><ArticleId IdType="pubmed">29692414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorenzini I., Moore S., Sattler R. RNA Editing Deficiency in Neurodegeneration. Adv. Neurobiol. 2018;20:63&#x2013;83. doi: 10.1007/978-3-319-89689-2_3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-89689-2_3</ArticleId><ArticleId IdType="pubmed">29916016</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikura K. Functions and regulation of RNA editing by ADAR deaminases. Annu. Rev. Biochem. 2010;79:321&#x2013;349. doi: 10.1146/annurev-biochem-060208-105251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-biochem-060208-105251</ArticleId><ArticleId IdType="pmc">PMC2953425</ArticleId><ArticleId IdType="pubmed">20192758</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y., Ito K., Sun H., Kanazawa I., Kwak S. Low editing efficiency of GluR2 mRNA is associated with a low relative abundance of ADAR2 mRNA in white matter of normal human brain. Eur. J. Neurosci. 2003;18:23&#x2013;33. doi: 10.1046/j.1460-9568.2003.02718.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2003.02718.x</ArticleId><ArticleId IdType="pubmed">12859334</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartner J.C., Schmittwolf C., Kispert A., Muller A.M., Higuchi M., Seeburg P.H. Liver disintegration in the mouse embryo caused by deficiency in the RNA-editing enzyme ADAR1. J. Biol. Chem. 2004;279:4894&#x2013;4902. doi: 10.1074/jbc.M311347200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311347200</ArticleId><ArticleId IdType="pubmed">14615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamura Y., Suzuki T., Kono M., Inagaki K., Ito S., Suzuki N., Tomita Y. Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am. J. Hum. Genet. 2003;73:693&#x2013;699. doi: 10.1086/378209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/378209</ArticleId><ArticleId IdType="pmc">PMC1180697</ArticleId><ArticleId IdType="pubmed">12916015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice G.I., Kasher P.R., Forte G.M., Mannion N.M., Greenwood S.M., Szynkiewicz M., Dickerson J.E., Bhaskar S.S., Zampini M., Briggs T.A., et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat. Genet. 2012;44:1243&#x2013;1248. doi: 10.1038/ng.2414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2414</ArticleId><ArticleId IdType="pmc">PMC4154508</ArticleId><ArticleId IdType="pubmed">23001123</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M., Maas S., Single F.N., Hartner J., Rozov A., Burnashev N., Feldmeyer D., Sprengel R., Seeburg P.H. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406:78&#x2013;81. doi: 10.1038/35017558.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017558</ArticleId><ArticleId IdType="pubmed">10894545</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan T.Y., Sedmik J., Fitzgerald M.P., Halevy R.S., Keegan L.P., Helbig I., Basel-Salmon L., Cohen L., Straussberg R., Chung W.K., et al. Bi-allelic ADARB1 Variants Associated with Microcephaly, Intellectual Disability, and Seizures. Am. J. Hum. Genet. 2020;106:467&#x2013;483. doi: 10.1016/j.ajhg.2020.02.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2020.02.015</ArticleId><ArticleId IdType="pmc">PMC7118584</ArticleId><ArticleId IdType="pubmed">32220291</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroofian R., Sedmik J., Mazaheri N., Scala M., Zaki M.S., Keegan L.P., Azizimalamiri R., Issa M., Shariati G., Sedaghat A., et al. Biallelic variants in ADARB1, encoding a dsRNA-specific adenosine deaminase, cause a severe developmental and epileptic encephalopathy. J. Med. Genet. 2020;11:36. doi: 10.1136/jmedgenet-2020-107048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2020-107048</ArticleId><ArticleId IdType="pmc">PMC8327408</ArticleId><ArticleId IdType="pubmed">32719099</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T., Yamashita T., Suzuki T., Tsuji S., Higuchi M., Seeburg P.H., Takahashi R., Misawa H., Kwak S. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J. Neurosci. 2010;30:11917&#x2013;11925. doi: 10.1523/JNEUROSCI.2021-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2021-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633551</ArticleId><ArticleId IdType="pubmed">20826656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang T., Park C.K., Leung A.K., Gao Y., Hyde T.M., Kleinman J.E., Rajpurohit A., Tao R., Shin J.H., Weinberger D.R. Dynamic regulation of RNA editing in human brain development and disease. Nat. Neurosci. 2016;19:1093&#x2013;1099. doi: 10.1038/nn.4337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4337</ArticleId><ArticleId IdType="pubmed">27348216</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A., Jantsch M.F. Transcript diversification in the nervous system: A to I RNA editing in CNS function and disease development. Front. Neurosci. 2012;6:99. doi: 10.3389/fnins.2012.00099.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2012.00099</ArticleId><ArticleId IdType="pmc">PMC3391646</ArticleId><ArticleId IdType="pubmed">22787438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal-Mark N., Shallev L., Sweetat S., Barak M., Billy Li J., Levanon E.Y., Eisenberg E., Behar O. Abnormalities in A-to-I RNA editing patterns in CNS injuries correlate with dynamic changes in cell type composition. Sci. Rep. 2017;7:43421. doi: 10.1038/srep43421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep43421</ArticleId><ArticleId IdType="pmc">PMC5339895</ArticleId><ArticleId IdType="pubmed">28266523</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran S.S., Jun H.I., Bahn J.H., Azghadi A., Ramaswami G., Van Nostrand E.L., Nguyen T.B., Hsiao Y.E., Lee C., Pratt G.A., et al. Widespread RNA editing dysregulation in brains from autistic individuals. Nat. Neurosci. 2019;22:25&#x2013;36. doi: 10.1038/s41593-018-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0287-x</ArticleId><ArticleId IdType="pmc">PMC6375307</ArticleId><ArticleId IdType="pubmed">30559470</ArticleId></ArticleIdList></Reference><Reference><Citation>Breen M.S., Dobbyn A., Li Q., Roussos P., Hoffman G.E., Stahl E., Chess A., Sklar P., Li J.B., Devlin B., et al. Global landscape and genetic regulation of RNA editing in cortical samples from individuals with schizophrenia. Nat. Neurosci. 2019;22:1402&#x2013;1412. doi: 10.1038/s41593-019-0463-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0463-7</ArticleId><ArticleId IdType="pmc">PMC6791127</ArticleId><ArticleId IdType="pubmed">31455887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y., Ito K., Sun H., Aizawa H., Kanazawa I., Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. doi: 10.1038/427801a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/427801a</ArticleId><ArticleId IdType="pubmed">14985749</ArticleId></ArticleIdList></Reference><Reference><Citation>Khermesh K., D&#x2019;Erchia A.M., Barak M., Annese A., Wachtel C., Levanon E.Y., Picardi E., Eisenberg E. Reduced levels of protein recoding by A-to-I RNA editing in Alzheimer&#x2019;s disease. RNA. 2016;22:290&#x2013;302. doi: 10.1261/rna.054627.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1261/rna.054627.115</ArticleId><ArticleId IdType="pmc">PMC4712678</ArticleId><ArticleId IdType="pubmed">26655226</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbarian S., Smith M.A., Jones E.G. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer&#x2019;s disease, Huntington&#x2019;s disease and schizophrenia. Brain Res. 1995;699:297&#x2013;304. doi: 10.1016/0006-8993(95)00922-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(95)00922-D</ArticleId><ArticleId IdType="pubmed">8616634</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaisler-Salomon I., Kravitz E., Feiler Y., Safran M., Biegon A., Amariglio N., Rechavi G. Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer&#x2019;s disease. Neurobiol. Aging. 2014;35:1785&#x2013;1791. doi: 10.1016/j.neurobiolaging.2014.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.02.018</ArticleId><ArticleId IdType="pubmed">24679603</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas S., Patt S., Schrey M., Rich A. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc. Natl. Acad. Sci. USA. 2001;98:14687&#x2013;14692. doi: 10.1073/pnas.251531398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.251531398</ArticleId><ArticleId IdType="pmc">PMC64742</ArticleId><ArticleId IdType="pubmed">11717408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiuchi S., Yoshida Y., Sugawara K., Aihara M., Ohtani T., Watanabe T., Saito N., Tsuzuki K., Okado H., Miwa A., et al. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J. Neurosci. 2007;27:7987&#x2013;8001. doi: 10.1523/JNEUROSCI.2180-07.2007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2180-07.2007</ArticleId><ArticleId IdType="pmc">PMC6672718</ArticleId><ArticleId IdType="pubmed">17652589</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenci C., Barzotti R., Galeano F., Corbelli S., Rota R., Massimi L., Di Rocco C., O&#x2019;Connell M.A., Gallo A. Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J. Biol. Chem. 2008;283:7251&#x2013;7260. doi: 10.1074/jbc.M708316200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M708316200</ArticleId><ArticleId IdType="pubmed">18178553</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil V., Pal J., Mahalingam K., Somasundaram K. Global RNA editome landscape discovers reduced RNA editing in glioma: Loss of editing of gamma-amino butyric acid receptor alpha subunit 3 (GABRA3) favors glioma migration and invasion. PeerJ. 2020;8:e9755. doi: 10.7717/peerj.9755.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.9755</ArticleId><ArticleId IdType="pmc">PMC7531343</ArticleId><ArticleId IdType="pubmed">33062411</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeano F., Rossetti C., Tomaselli S., Cifaldi L., Lezzerini M., Pezzullo M., Boldrini R., Massimi L., Di Rocco C.M., Locatelli F., et al. ADAR2-editing activity inhibits glioblastoma growth through the modulation of the CDC14B/Skp2/p21/p27 axis. Oncogene. 2013;32:998&#x2013;1009. doi: 10.1038/onc.2012.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/onc.2012.125</ArticleId><ArticleId IdType="pmc">PMC3579159</ArticleId><ArticleId IdType="pubmed">22525274</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury Y., Tay F.C., Lam D.H., Sandanaraj E., Tang C., Ang B.T., Wang S. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J. Clin. Investig. 2012;122:4059&#x2013;4076. doi: 10.1172/JCI62925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI62925</ArticleId><ArticleId IdType="pmc">PMC3484441</ArticleId><ArticleId IdType="pubmed">23093778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesarini V., Silvestris D.A., Tassinari V., Tomaselli S., Alon S., Eisenberg E., Locatelli F., Gallo A. ADAR2/miR-589-3p axis controls glioblastoma cell migration/invasion. Nucleic Acids. Res. 2018;46:2045&#x2013;2059. doi: 10.1093/nar/gkx1257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkx1257</ArticleId><ArticleId IdType="pmc">PMC5829642</ArticleId><ArticleId IdType="pubmed">29267965</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S., Lau L., Wei J., Zhu D., Zou S., Sun H.S., Fu Y., Liu F., Lu Y. Expression of Ca(2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neuron. 2004;43:43&#x2013;55. doi: 10.1016/j.neuron.2004.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.06.017</ArticleId><ArticleId IdType="pubmed">15233916</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng P.L., Zhong X., Tu W., Soundarapandian M.M., Molner P., Zhu D., Lau L., Liu S., Liu F., Lu Y. ADAR2-dependent RNA editing of AMPA receptor subunit GluR2 determines vulnerability of neurons in forebrain ischemia. Neuron. 2006;49:719&#x2013;733. doi: 10.1016/j.neuron.2006.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.01.025</ArticleId><ArticleId IdType="pubmed">16504947</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbon A., Fumagalli F., Caracciolo L., Madaschi L., Lesma E., Mora C., Carelli S., Slotkin T.A., Racagni G., Di Giulio A.M., et al. Acute spinal cord injury persistently reduces R/G RNA editing of AMPA receptors. J. Neurochem. 2010;114:397&#x2013;407. doi: 10.1111/j.1471-4159.2010.06767.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06767.x</ArticleId><ArticleId IdType="pubmed">20456005</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Narzo A.F., Kozlenkov A., Ge Y., Zhang B., Sanelli L., May Z., Li Y., Fouad K., Cardozo C., Koonin E.V., et al. Decrease of mRNA Editing after Spinal Cord Injury is Caused by Down-regulation of ADAR2 that is Triggered by Inflammatory Response. Sci. Rep. 2015;5:12615. doi: 10.1038/srep12615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12615</ArticleId><ArticleId IdType="pmc">PMC4519770</ArticleId><ArticleId IdType="pubmed">26223940</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijs R.D., Surges R., O&#x2019;Brien T.J., Sander J.W. Epilepsy in adults. Lancet. 2019;393:689&#x2013;701. doi: 10.1016/S0140-6736(18)32596-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32596-0</ArticleId><ArticleId IdType="pubmed">30686584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortenbruck G., Berger E., Speckmann E.J., Musshoff U. RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients. Neurobiol. Dis. 2001;8:459&#x2013;468. doi: 10.1006/nbdi.2001.0394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2001.0394</ArticleId><ArticleId IdType="pubmed">11442354</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmar W., Gloger J., Berger E., Kortenbruck G., Kohling R., Speckmann E.J., Musshoff U. RNA editing (R/G site) and flip-flop splicing of the AMPA receptor subunit GluR2 in nervous tissue of epilepsy patients. Neurobiol. Dis. 2004;15:371&#x2013;379. doi: 10.1016/j.nbd.2003.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2003.11.006</ArticleId><ArticleId IdType="pubmed">15006707</ArticleId></ArticleIdList></Reference><Reference><Citation>Krestel H., Raffel S., von Lehe M., Jagella C., Moskau-Hartmann S., Becker A., Elger C.E., Seeburg P.H., Nirkko A. Differences between RNA and DNA due to RNA editing in temporal lobe epilepsy. Neurobiol. Dis. 2013;56:66&#x2013;73. doi: 10.1016/j.nbd.2013.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.04.006</ArticleId><ArticleId IdType="pubmed">23607937</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard A., Ferhat L., Dessi F., Charton G., Represa A., Ben-Ari Y., Khrestchatisky M. Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: Evidence for independent developmental, pathological and cellular regulation. Eur. J. Neurosci. 1999;11:604&#x2013;616. doi: 10.1046/j.1460-9568.1999.00479.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.1999.00479.x</ArticleId><ArticleId IdType="pubmed">10051761</ArticleId></ArticleIdList></Reference><Reference><Citation>Caracciolo L., Barbon A., Palumbo S., Mora C., Toscano C.D., Bosetti F., Barlati S. Altered mRNA editing and expression of ionotropic glutamate receptors after kainic acid exposure in cyclooxygenase-2 deficient mice. PLoS ONE. 2011;6:e19398. doi: 10.1371/journal.pone.0019398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0019398</ArticleId><ArticleId IdType="pmc">PMC3093380</ArticleId><ArticleId IdType="pubmed">21589914</ArticleId></ArticleIdList></Reference><Reference><Citation>Malhi G.S., Mann J.J. Depression. Lancet. 2018;392:2299&#x2013;2312. doi: 10.1016/S0140-6736(18)31948-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31948-2</ArticleId><ArticleId IdType="pubmed">30396512</ArticleId></ArticleIdList></Reference><Reference><Citation>Niswender C.M., Herrick-Davis K., Dilley G.E., Meltzer H.Y., Overholser J.C., Stockmeier C.A., Emeson R.B., Sanders-Bush E. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology. 2001;24:478&#x2013;491. doi: 10.1016/S0893-133X(00)00223-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0893-133X(00)00223-2</ArticleId><ArticleId IdType="pubmed">11282248</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurevich I., Tamir H., Arango V., Dwork A.J., Mann J.J., Schmauss C. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron. 2002;34:349&#x2013;356. doi: 10.1016/S0896-6273(02)00660-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00660-8</ArticleId><ArticleId IdType="pubmed">11988167</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto K., Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci. Lett. 2003;346:169&#x2013;172. doi: 10.1016/S0304-3940(03)00608-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00608-6</ArticleId><ArticleId IdType="pubmed">12853111</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu H., Urban D.J., Blashka J., McPheeters M.T., Kroeze W.K., Mieczkowski P., Overholser J.C., Jurjus G.J., Dieter L., Mahajan G.J., et al. Quantitative analysis of focused a-to-I RNA editing sites by ultra-high-throughput sequencing in psychiatric disorders. PLoS ONE. 2012;7:e43227. doi: 10.1371/journal.pone.0043227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0043227</ArticleId><ArticleId IdType="pmc">PMC3422315</ArticleId><ArticleId IdType="pubmed">22912834</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann D., van der Laan S., Underwood M.D., Salvetat N., Cavarec L., Vincent L., Molina F., Mann J.J., Arango V., Pujol J.F. Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. Transl. Psychiatry. 2016;6:e878. doi: 10.1038/tp.2016.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.121</ArticleId><ArticleId IdType="pmc">PMC5022077</ArticleId><ArticleId IdType="pubmed">27576167</ArticleId></ArticleIdList></Reference><Reference><Citation>Sodhi M.S., Burnet P.W., Makoff A.J., Kerwin R.W., Harrison P.J. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol. Psychiatry. 2001;6:373&#x2013;379. doi: 10.1038/sj.mp.4000920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4000920</ArticleId><ArticleId IdType="pubmed">11443520</ArticleId></ArticleIdList></Reference><Reference><Citation>Dracheva S., Patel N., Woo D.A., Marcus S.M., Siever L.J., Haroutunian V. Increased serotonin 2C receptor mRNA editing: A possible risk factor for suicide. Mol. Psychiatry. 2008;13:1001&#x2013;1010. doi: 10.1038/sj.mp.4002081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4002081</ArticleId><ArticleId IdType="pubmed">17848916</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimienti F., Cavarec L., Vincent L., Salvetat N., Arango V., Underwood M.D., Mann J.J., Pujol J.F., Weissmann D. Brain region-specific alterations of RNA editing in PDE8A mRNA in suicide decedents. Transl. Psychiatry. 2019;9:91. doi: 10.1038/s41398-018-0331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-018-0331-3</ArticleId><ArticleId IdType="pmc">PMC6377659</ArticleId><ArticleId IdType="pubmed">30770787</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvetat N., Chimienti F., Cayzac C., Dubuc B., Checa-Robles F., Dupre P., Mereuze S., Patel V., Genty C., Lang J.P., et al. Phosphodiesterase 8A to discriminate in blood samples depressed patients and suicide attempters from healthy controls based on A-to-I RNA editing modifications. Transl. Psychiatry. 2021;11:255. doi: 10.1038/s41398-021-01377-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01377-9</ArticleId><ArticleId IdType="pmc">PMC8087806</ArticleId><ArticleId IdType="pubmed">33931591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lord C., Elsabbagh M., Baird G., Veenstra-Vanderweele J. Autism spectrum disorder. Lancet. 2018;392:508&#x2013;520. doi: 10.1016/S0140-6736(18)31129-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31129-2</ArticleId><ArticleId IdType="pmc">PMC7398158</ArticleId><ArticleId IdType="pubmed">30078460</ArticleId></ArticleIdList></Reference><Reference><Citation>Eran A., Li J.B., Vatalaro K., McCarthy J., Rahimov F., Collins C., Markianos K., Margulies D.M., Brown E.N., Calvo S.E., et al. Comparative RNA editing in autistic and neurotypical cerebella. Mol. Psychiatry. 2013;18:1041&#x2013;1048. doi: 10.1038/mp.2012.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2012.118</ArticleId><ArticleId IdType="pmc">PMC3494744</ArticleId><ArticleId IdType="pubmed">22869036</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H.D., McFarland K.N., Darnell S.B., Huizenga M.N., Sangrey G.R., Cha J.H., Pierce R.C., Sadri-Vakili G. ADAR2-dependent GluA2 editing regulates cocaine seeking. Mol. Psychiatry. 2015;20:1460&#x2013;1466. doi: 10.1038/mp.2014.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2014.134</ArticleId><ArticleId IdType="pmc">PMC4412769</ArticleId><ArticleId IdType="pubmed">25349168</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M., Watanabe Y. RNA Editing of Serotonin 2C Receptor and Alcohol Intake. Front. Neurosci. 2019;13:1390. doi: 10.3389/fnins.2019.01390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01390</ArticleId><ArticleId IdType="pmc">PMC6971223</ArticleId><ArticleId IdType="pubmed">32009879</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr A., Sattler R. Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD. Brain Res. 2018;1693:98&#x2013;108. doi: 10.1016/j.brainres.2018.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.02.011</ArticleId><ArticleId IdType="pmc">PMC5997509</ArticleId><ArticleId IdType="pubmed">29453960</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosaka T., Yamashita T., Tamaoka A., Kwak S. Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases. Int. J. Mol. Sci. 2019;20:3148. doi: 10.3390/ijms20133148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133148</ArticleId><ArticleId IdType="pmc">PMC6651127</ArticleId><ArticleId IdType="pubmed">31252669</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnashev N., Monyer H., Seeburg P.H., Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron. 1992;8:189&#x2013;198. doi: 10.1016/0896-6273(92)90120-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(92)90120-3</ArticleId><ArticleId IdType="pubmed">1370372</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmeyer D., Kask K., Brusa R., Kornau H.C., Kolhekar R., Rozov A., Burnashev N., Jensen V., Hvalby O., Sprengel R., et al. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat. Neurosci. 1999;2:57&#x2013;64. doi: 10.1038/4561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/4561</ArticleId><ArticleId IdType="pubmed">10195181</ArticleId></ArticleIdList></Reference><Reference><Citation>Seeburg P.H. A-to-I editing: New and old sites, functions and speculations. Neuron. 2002;35:17&#x2013;20. doi: 10.1016/S0896-6273(02)00760-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00760-2</ArticleId><ArticleId IdType="pubmed">12123604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z., Agopyan N., Miu P., Xiong Z., Henderson J., Gerlai R., Taverna F.A., Velumian A., MacDonald J., Carlen P., et al. Enhanced LTP in mice deficient in the AMPA receptor GluR2. Neuron. 1996;17:945&#x2013;956. doi: 10.1016/S0896-6273(00)80225-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80225-1</ArticleId><ArticleId IdType="pubmed">8938126</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Erchia A.M., Gallo A., Manzari C., Raho S., Horner D.S., Chiara M., Valletti A., Aiello I., Mastropasqua F., Ciaccia L., et al. Massive transcriptome sequencing of human spinal cord tissues provides new insights into motor neuron degeneration in ALS. Sci. Rep. 2017;7:10046. doi: 10.1038/s41598-017-10488-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-10488-7</ArticleId><ArticleId IdType="pmc">PMC5577269</ArticleId><ArticleId IdType="pubmed">28855684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichiyanagi N., Fujimori K., Yano M., Ishihara-Fujisaki C., Sone T., Akiyama T., Okada Y., Akamatsu W., Matsumoto T., Ishikawa M., et al. Establishment of In Vitro FUS-Associated Familial Amyotrophic Lateral Sclerosis Model Using Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2016;6:496&#x2013;510. doi: 10.1016/j.stemcr.2016.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4834049</ArticleId><ArticleId IdType="pubmed">26997647</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory J.M., Livesey M.R., McDade K., Selvaraj B.T., Barton S.K., Chandran S., Smith C. Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain. J. Pathol. 2020;250:67&#x2013;78. doi: 10.1002/path.5351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5351</ArticleId><ArticleId IdType="pmc">PMC6973025</ArticleId><ArticleId IdType="pubmed">31579943</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H., Sawada J., Hideyama T., Yamashita T., Katayama T., Hasebe N., Kimura T., Yahara O., Kwak S. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120:75&#x2013;84. doi: 10.1007/s00401-010-0678-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0678-x</ArticleId><ArticleId IdType="pubmed">20372915</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T., Kwak S. The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Brain Res. 2014;1584:28&#x2013;38. doi: 10.1016/j.brainres.2013.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2013.12.011</ArticleId><ArticleId IdType="pubmed">24355598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T., Hideyama T., Hachiga K., Teramoto S., Takano J., Iwata N., Saido T.C., Kwak S. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat. Commun. 2012;3:1307. doi: 10.1038/ncomms2303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2303</ArticleId><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T., Kwak S. When Does ALS Start? ADAR2-GluA2 Hypothesis for the Etiology of Sporadic ALS. Front. Mol. Neurosci. 2011;4:33. doi: 10.3389/fnmol.2011.00033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2011.00033</ArticleId><ArticleId IdType="pmc">PMC3214764</ArticleId><ArticleId IdType="pubmed">22102833</ArticleId></ArticleIdList></Reference><Reference><Citation>Tischbein M., Baron D.M., Lin Y.C., Gall K.V., Landers J.E., Fallini C., Bosco D.A. The RNA-binding protein FUS/TLS undergoes calcium-mediated nuclear egress during excitotoxic stress and is required for GRIA2 mRNA processing. J. Biol. Chem. 2019;294:10194&#x2013;10210. doi: 10.1074/jbc.RA118.005933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.RA118.005933</ArticleId><ArticleId IdType="pmc">PMC6664169</ArticleId><ArticleId IdType="pubmed">31092554</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigoriev V.V., Efimova A.D., Ustyugov A.A., Shevchenko V.P., Bachurin S.O., Myasoedov N.F. Glutamate release and uptake processes are altered in a new mouse model of amyotrophic lateral sclerosis. Dokl. Biochem. Biophys. 2016;468:165&#x2013;167. doi: 10.1134/S1607672916030017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S1607672916030017</ArticleId><ArticleId IdType="pubmed">27417710</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H., Hideyama T., Yamashita T., Kimura T., Suzuki N., Aoki M., Kwak S. Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUS(P525L) mutation. J. Clin. Neurosci. 2016;32:128&#x2013;129. doi: 10.1016/j.jocn.2015.12.039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2015.12.039</ArticleId><ArticleId IdType="pubmed">27343041</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S., Alsop E., Lorenzini I., Starr A., Rabichow B.E., Mendez E., Levy J.L., Burciu C., Reiman R., Chew J., et al. ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD. Acta Neuropathol. 2019;19:1999. doi: 10.1007/s00401-019-01999-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-01999-w</ArticleId><ArticleId IdType="pmc">PMC6750285</ArticleId><ArticleId IdType="pubmed">30945056</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki H., Matsuoka M. Proline-arginine poly-dipeptide encoded by the C9orf72 repeat expansion inhibits adenosine deaminase acting on RNA. J. Neurochem. 2021;158:753&#x2013;765. doi: 10.1111/jnc.15445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15445</ArticleId><ArticleId IdType="pubmed">34081786</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj B.T., Livesey M.R., Zhao C., Gregory J.M., James O.T., Cleary E.M., Chouhan A.K., Gane A.B., Perkins E.M., Dando O., et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca(2+)-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 2018;9:347. doi: 10.1038/s41467-017-02729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02729-0</ArticleId><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinones-Valdez G., Tran S.S., Jun H.I., Bahn J.H., Yang E.W., Zhan L., Brummer A., Wei X., Van Nostrand E.L., Pratt G.A., et al. Regulation of RNA editing by RNA-binding proteins in human cells. Commun. Biol. 2019;2:19. doi: 10.1038/s42003-018-0271-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-018-0271-8</ArticleId><ArticleId IdType="pmc">PMC6331435</ArticleId><ArticleId IdType="pubmed">30652130</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgomori T., Yamasaki R., Takeuchi H., Kadomatsu K., Kira J.I., Jinno S. Differential involvement of vesicular and glial glutamate transporters around spinal alpha-motoneurons in the pathogenesis of SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neuroscience. 2017;356:114&#x2013;124. doi: 10.1016/j.neuroscience.2017.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2017.05.014</ArticleId><ArticleId IdType="pubmed">28526579</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino T., Provenzano F., Gallia E., Ravera S., Torazza C., Bossi S., Ferrando S., Puliti A., Van Den Bosch L., Bonanno G., et al. In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2019;129:79&#x2013;92. doi: 10.1016/j.nbd.2019.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.05.007</ArticleId><ArticleId IdType="pubmed">31102766</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y., Sun H., Ito K., Hideyama T., Aoki M., Sobue G., Tsuji S., Kwak S. Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in ALS1 or SBMA. Neurosci. Res. 2006;54:11&#x2013;14. doi: 10.1016/j.neures.2005.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2005.09.006</ArticleId><ArticleId IdType="pubmed">16225946</ArticleId></ArticleIdList></Reference><Reference><Citation>Udagawa T., Fujioka Y., Tanaka M., Honda D., Yokoi S., Riku Y., Ibi D., Nagai T., Yamada K., Watanabe H., et al. FUS regulates AMPA receptor function and FTLD/ALS-associated behaviour via GluA1 mRNA stabilization. Nat. Commun. 2015;6:7098. doi: 10.1038/ncomms8098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8098</ArticleId><ArticleId IdType="pmc">PMC4479014</ArticleId><ArticleId IdType="pubmed">25968143</ArticleId></ArticleIdList></Reference><Reference><Citation>Capauto D., Colantoni A., Lu L., Santini T., Peruzzi G., Biscarini S., Morlando M., Shneider N.A., Caffarelli E., Laneve P., et al. A Regulatory Circuitry Between Gria2, miR-409, and miR-495 Is Affected by ALS FUS Mutation in ESC-Derived Motor Neurons. Mol. Neurobiol. 2018;55:7635&#x2013;7651. doi: 10.1007/s12035-018-0884-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0884-4</ArticleId><ArticleId IdType="pmc">PMC6132778</ArticleId><ArticleId IdType="pubmed">29430619</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R., Barbagallo P., Farrimond L., Candalija A., Scaber J., Ababneh N.A., Sathyaprakash C., Vowles J., Cowley S.A., Talbot K. Impairment of Mitochondrial Calcium Buffering Links Mutations in C9ORF72 and TARDBP in iPS-Derived Motor Neurons from Patients with ALS/FTD. Stem Cell Rep. 2020;14:892&#x2013;908. doi: 10.1016/j.stemcr.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Bursch F., Kalmbach N., Naujock M., Staege S., Eggenschwiler R., Abo-Rady M., Japtok J., Guo W., Hensel N., Reinhardt P., et al. Altered calcium dynamics and glutamate receptor properties in iPSC-derived motor neurons from ALS patients with C9orf72, FUS, SOD1 or TDP43 mutations. Hum. Mol. Genet. 2019;28:2835&#x2013;2850. doi: 10.1093/hmg/ddz107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddz107</ArticleId><ArticleId IdType="pubmed">31108504</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L.D., Ohman M. ADAR1 Editing and its Role in Cancer. Genes. 2018;10:12. doi: 10.3390/genes10010012.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes10010012</ArticleId><ArticleId IdType="pmc">PMC6356570</ArticleId><ArticleId IdType="pubmed">30585209</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M., Zimmerman M.B., Beltz T.G., Johnson A.K. Affect-related behaviors in mice misexpressing the RNA editing enzyme ADAR2. Physiol. Behav. 2009;97:446&#x2013;454. doi: 10.1016/j.physbeh.2009.03.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.physbeh.2009.03.029</ArticleId><ArticleId IdType="pmc">PMC2778280</ArticleId><ArticleId IdType="pubmed">19361536</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T., Chai H.L., Teramoto S., Tsuji S., Shimazaki K., Muramatsu S., Kwak S. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol. Med. 2013;5:1710&#x2013;1719. doi: 10.1002/emmm.201302935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/emmm.201302935</ArticleId><ArticleId IdType="pmc">PMC3840487</ArticleId><ArticleId IdType="pubmed">24115583</ArticleId></ArticleIdList></Reference><Reference><Citation>High K.A., Roncarolo M.G. Gene Therapy. N. Engl. J. Med. 2019;381:455&#x2013;464. doi: 10.1056/NEJMra1706910.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1706910</ArticleId><ArticleId IdType="pubmed">31365802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariyawasam D., Alexander I.E., Kurian M., Farrar M.A. Great expectations: Virus-mediated gene therapy in neurological disorders. J. Neurol. Neurosurg. Psychiatry. 2020;91:849&#x2013;860. doi: 10.1136/jnnp-2019-322327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322327</ArticleId><ArticleId IdType="pubmed">32503884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox D.B.T., Gootenberg J.S., Abudayyeh O.O., Franklin B., Kellner M.J., Joung J., Zhang F. RNA editing with CRISPR-Cas13. Science. 2017;358:1019&#x2013;1027. doi: 10.1126/science.aaq0180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaq0180</ArticleId><ArticleId IdType="pmc">PMC5793859</ArticleId><ArticleId IdType="pubmed">29070703</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P., Qin S., Pu Q., Wang Z., Wu Q., Gao P., Schettler J., Guo K., Li R., Li G., et al. CRISPR-Cas13 Inhibitors Block RNA Editing in Bacteria and Mammalian Cells. Mol. Cell. 2020;78:850&#x2013;861.e5. doi: 10.1016/j.molcel.2020.03.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2020.03.033</ArticleId><ArticleId IdType="pmc">PMC7299153</ArticleId><ArticleId IdType="pubmed">32348779</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Zhou Y., Xiao Q., He B., Geng G., Wang Z., Cao B., Dong X., Bai W., Wang Y., et al. Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nat. Methods. 2021;18:499&#x2013;506. doi: 10.1038/s41592-021-01124-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-021-01124-4</ArticleId><ArticleId IdType="pubmed">33941935</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L., Vandenberghe W., Klaassen H., Van Houtte E., Robberecht W. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J. Neurol. Sci. 2000;180:29&#x2013;34. doi: 10.1016/S0022-510X(00)00414-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(00)00414-7</ArticleId><ArticleId IdType="pubmed">11090861</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P., Leyssen M., Callewaert G., Robberecht W., Van Den Bosch L. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. 2003;343:81&#x2013;84. doi: 10.1016/S0304-3940(03)00314-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00314-8</ArticleId><ArticleId IdType="pubmed">12759169</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M., Yamashita T., Hirose N., Teramoto S., Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci. Rep. 2016;6:28649. doi: 10.1038/srep28649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28649</ArticleId><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B., Mauricio E.A., Shah J.S., Li Z., Rogawski M.A. Cortical excitability threshold can be increased by the AMPA blocker Perampanel in amyotrophic lateral sclerosis. Muscle Nerve. 2021;64:215&#x2013;219. doi: 10.1002/mus.27328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27328</ArticleId><ArticleId IdType="pubmed">34008857</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzi R.M., Shefner J., Chappell A.S., Bjerke J.S., Tamura R., Chaudhry V., Clawson L., Haas L., Rothstein J.D. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. 2010;11:266&#x2013;271. doi: 10.3109/17482960903307805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903307805</ArticleId><ArticleId IdType="pubmed">19961264</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H., Kato H., Oba K., Kawahara T., Okubo Y., Saito T., Naito M., Urushitani M., Tamaoka A., Nakamagoe K., et al. Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J. Neurol. 2021;7:21. doi: 10.1007/s00415-021-10670-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10670-y</ArticleId><ArticleId IdType="pubmed">34191081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosaka T., Yamashita T., Teramoto S., Hirose N., Tamaoka A., Kwak S. ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs. Neurosci. Res. 2018;11:5. doi: 10.1016/j.neures.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2018.11.005</ArticleId><ArticleId IdType="pubmed">30448461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>